Li Ming Xiao

7208311, Apr 24, 2007

Dec 19, 2003

10/741204

Wenyan Wang - Edison NJ, US
Hung V. Le - Rockaway NJ, US
Jian-Jun Liu - Parlin NJ, US
Vincent S. Madison - Mountain Lakes NJ, US
Winifred W. Prosise - Ramsey NJ, US
Shahriar Shane Taremi - Upper Montclair NJ, US
Li Xiao - Woodbridge NJ, US
Jun Zou - Cranbury NJ, US

Schering Corporation - Kenilworth NJ

C12N 9/64
C12N 15/12
C12N 15/57
C12N 15/79

435226, 435 691, 4352523, 4353201, 435471

The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.

7335758, Feb 26, 2008

Oct 2, 2006

11/541982

Wenyan Wang - Edison NJ, US
Hung V. Le - Rockaway NJ, US
Jian-Jun Liu - Parlin NJ, US
Vincent S. Madison - Mountain Lakes NJ, US
Winifred W. Prosise - Ramsey NJ, US
Shahriar Shane Taremi - Upper Montclair NJ, US
Li Xiao - Woodbridge NJ, US
Jun Zou - Cranbury NJ, US

Schering Corporation - Kenilworth NJ

C12N 15/12
C12N 15/17
C12N 15/79
C12N 9/64

536 232, 435226, 435 691, 4352523, 4353201

The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.

7528132, May 5, 2009

Jan 24, 2006

11/338501

Tin-Yau Chan - Edison NJ, US
Thierry O. Fischmann - Scotch Plains NJ, US
Mark A. McCoy - Randolph NJ, US
Brian A. McKittrick - Vernon NJ, US
Andrew J. Prongay - Stewartsville NJ, US
Haiyan Pu - Morris Plains NJ, US
Li Wang - Nanuet NY, US
Li Xiao - Cranbury NJ, US

Schering Corporation - Kenilworth NJ

C07D 403/12
C07D 403/14
A61K 31/53
A61P 35/00

514241, 544182

A compound having the general structure of Formula (I):.

7700601, Apr 20, 2010

Mar 28, 2007

11/729020

Tin-Yau Chan - Edison NJ, US
Brian A. McKittrick - New Vernon NJ, US
Haiyan Pu - Livingston NJ, US
Liwu Hong - Edison NJ, US
Andrew J. Prongay - Stewartsville NJ, US
Li Xiao - Cranbury NJ, US
Mark A. McCoy - Randolph NJ, US

Schering Corporation - Kenilworth NJ

A61K 31/4965

51425505, 544359, 544405, 5483611

Disclosed is a compound of the formula:.

8546404, Oct 1, 2013

Jun 5, 2007

11/810282

Alan B. Cooper - West Caldwell NJ, US
Yongqi Deng - Newton MA, US
Neng-Yang Shih - Lexington MA, US
Hugh Y. Zhu - Scotch Plains NJ, US
Robert Sun - Natick MA, US
Joseph M. Kelly - Parlin NJ, US
Ronald J. Doll - Convent Station NJ, US
Yang Nan - Malden MA, US
Tong Wang - Cambridge MA, US
Jagdish A. Desai - Monroe Township NJ, US
James J-S Wang - Westfield NJ, US
Youhao Dong - Cambridge MA, US
Vincent S. Madison - Mountain Lakes NJ, US
Li Xiao - Cranbury NJ, US
Alan W. Hruza - Hackettstown NJ, US
M. Arshad Siddiqui - Newton MA, US
Ahmed A. Samatar - West Windsor NJ, US
Sunil Paliwal - Monroe Township NJ, US
Azim Alan Celebi - Clark NJ, US
Yiji Wu - Scotch Plains NJ, US
Sobhana Babu Boga - Scotch Plains NJ, US
Abdul-Basit Alhassan - Scotch Plains NJ, US
Xiaolei Gao - Scotch Plains NJ, US
Liang Zhu - Somerville MA, US
Mehul Patel - Waltham MA, US

Merck Sharp & Dohme - Rahway NJ

A01N 43/54
C07D 239/42
C07D 401/04

514256, 514247, 514277, 514396, 544315, 546 1, 546184, 5463611, 5483561, 5483601

Disclosed are the ERK inhibitors of formula 1. 0:.

20070191604, Aug 16, 2007

Dec 11, 2006

11/636954

Alan Cooper - West Caldwell NJ, US
Yongqi Deng - Newton MA, US
Gerald Shipps - Stoneham MA, US
Neng-Yang Shih - Warren NJ, US
Hugh Zhu - Scotch Plains NJ, US
Robert Sun - Berkeley Heights NJ, US
Joseph Kelly - Cambridge MA, US
Ronald Doll - Convent Station NJ, US
Yang Nan - Malden MA, US
Tong Wang - Cambridge MA, US
Jagdish Desai - Monroe Township NJ, US
James Wang - Westfield NJ, US
Youhao Dong - Cambridge MA, US
Vincent Madison - Mountain Lakes NJ, US
Li Xiao - Cranbury NJ, US
Alan Hruza - Hackettstown NJ, US
M. Siddiqui - Newton MA, US
Ahmed Samatar - West Windsor NJ, US
Sunil Paliwal - Monroe Township NJ, US
Azim Celebi - Clark NJ, US
Yiji Wu - Scotch Plains NJ, US
Sobhana Boga - Scotch Plains NJ, US

C07D 417/14
C07D 413/14
C07D 403/14

544060000, 544372000, 544140000, 546199000, 548361100

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

20080199447, Aug 21, 2008

Dec 20, 2007

11/961237

Wenyan Wang - Edison NJ, US
Hung V. Le - Rockaway NJ, US
Jian-Jun Liu - Lyon, CA
Vincent S. Madison - Mountain Lakes NJ, US
Winifred W. Prosise - Ramsey NJ, US
Shahriar Shane Taremi - Upper Montclair NJ, US
Li Xiao - Cranbury NJ, US
Jun Zou - Cranbury NJ, US

A61K 38/43
C12N 9/00
C12N 15/11
C12N 15/00
A61P 11/00
A61K 31/70
C12N 5/06
C12P 21/04

424 941, 435183, 536 232, 4353201, 435325, 435 691, 514 44

The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.

20230008022, Jan 12, 2023

Nov 25, 2019

17/295497

Dane CLAUSEN - Kenilworth NJ, US
Ping CHEN - Kenilworth NJ, US
Xavier FRADERA - Boston MA, US
Liangqin GUO - Kenilworth NJ, US
Yongxin HAN - Boston MA, US
Shuwen HE - Fanwood NJ, US
Xianhai HUANG - Warren NJ, US
Joseph KOZLOWSKI - Princeton NJ, US
Guoqing LI - Kenilworth NJ, US
Theodore A. MARTINOT - Southborough MA, US
Alexander PASTERNAK - Boston MA, US
Andreas VERRAS - New York NY, US
Li XIAO - Kenilworth NJ, US
Wensheng YU - Kenilworth NJ, US
Rui ZHANG - Kenilworth NJ, US
- Rahway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 231/56
C07D 491/052
C07D 231/54
A61K 31/496
C07D 401/12
C07D 401/14
C07D 413/12
A61K 31/5377
C07D 498/10
C07D 491/107
C07D 498/08
C07D 471/10
C07D 403/12
C07D 405/12
C07D 498/04
C07D 487/04
C07D 487/10
A61K 31/541
C07D 413/14

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.